PTLA stock forecast
Our latest prediction for Portola Pharmaceuticals, Inc.'s stock price was made on the April 4, 2019 when the stock price was at 37.41$.
In the short term (2weeks), PTLA's stock price should underperform the market by -0.45%. During that period the price should oscillate between -7.70% and +7.72%.
In the medium term (3months), PTLA's stock price should underperform the market by -1.19%. During that period the price should oscillate between -19.07% and +22.91%.Get email alerts
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
At the moment the company generates 40M USD in revenues.
On its last earning announcement, the company reported a loss of -5.31$ per share.
The book value per share is 3.29$
Three months stock forecastApril 4, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|